Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0ZLYPK)
| ADC Name |
FH-006
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
FH-006
Click to Show/Hide
|
|||||
| Organization |
Jiangsu Hengrui Pharmaceuticals (Originator);Fuhong Biotech (Originator)
|
|||||
| Drug Status |
Phase 2
|
|||||
| Drug-to-Antibody Ratio |
6
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
MG2303
|
Antibody Info | ||||
| Antigen Name |
CD276 antigen; Epidermal growth factor receptor (EGFR)
|
Antigen Info | ||||
| Payload Name |
SHR9265
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mc-Gly-Gly-Phe-Gly
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
rezetecan
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | |||
|---|---|---|---|---|---|---|---|
| Unspecific solid tumor |
2 Trials
|